Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Synergistic Lethality of a Binary Inhibitor of Mycobacterium tuberculosis KasA.

Kumar P, Capodagli GC, Awasthi D, Shrestha R, Maharaja K, Sukheja P, Li SG, Inoyama D, Zimmerman M, Ho Liang HP, Sarathy J, Mina M, Rasic G, Russo R, Perryman AL, Richmann T, Gupta A, Singleton E, Verma S, Husain S, Soteropoulos P, Wang Z, Morris R, Porter G, Agnihotri G, Salgame P, Ekins S, Rhee KY, Connell N, Dartois V, Neiditch MB, Freundlich JS, Alland D.

MBio. 2018 Dec 18;9(6). pii: e02101-17. doi: 10.1128/mBio.02101-17.

2.

Antimycobacterial Metabolism: Illuminating Mycobacterium tuberculosis Biology and Drug Discovery.

Awasthi D, Freundlich JS.

Trends Microbiol. 2017 Sep;25(9):756-767. doi: 10.1016/j.tim.2017.05.007. Epub 2017 Jun 13. Review.

3.

Strategic incorporation of fluorine in the drug discovery of new-generation antitubercular agents targeting bacterial cell division protein FtsZ.

Ojima I, Awasthi D, Wei L, Haranahalli K.

J Fluor Chem. 2017 Apr;196:44-56. doi: 10.1016/j.jfluchem.2016.07.020. Epub 2016 Jul 29.

4.

A Novel Small-Molecule Inhibitor of the Mycobacterium tuberculosis Demethylmenaquinone Methyltransferase MenG Is Bactericidal to Both Growing and Nutritionally Deprived Persister Cells.

Sukheja P, Kumar P, Mittal N, Li SG, Singleton E, Russo R, Perryman AL, Shrestha R, Awasthi D, Husain S, Soteropoulos P, Brukh R, Connell N, Freundlich JS, Alland D.

MBio. 2017 Feb 14;8(1). pii: e02022-16. doi: 10.1128/mBio.02022-16.

5.

Cell division inhibitors with efficacy equivalent to isoniazid in the acute murine Mycobacterium tuberculosis infection model.

Knudson SE, Awasthi D, Kumar K, Carreau A, Goullieux L, Lagrange S, Vermet H, Ojima I, Slayden RA.

J Antimicrob Chemother. 2015 Nov;70(11):3070-3. doi: 10.1093/jac/dkv226. Epub 2015 Aug 5.

6.

SB-RA-2001 inhibits bacterial proliferation by targeting FtsZ assembly.

Singh D, Bhattacharya A, Rai A, Dhaked HP, Awasthi D, Ojima I, Panda D.

Biochemistry. 2014 May 13;53(18):2979-92. doi: 10.1021/bi401356y. Epub 2014 May 1.

7.

In vitro-in vivo activity relationship of substituted benzimidazole cell division inhibitors with activity against Mycobacterium tuberculosis.

Knudson SE, Kumar K, Awasthi D, Ojima I, Slayden RA.

Tuberculosis (Edinb). 2014 May;94(3):271-6. doi: 10.1016/j.tube.2014.03.007. Epub 2014 Apr 1.

8.

A trisubstituted benzimidazole cell division inhibitor with efficacy against Mycobacterium tuberculosis.

Knudson SE, Awasthi D, Kumar K, Carreau A, Goullieux L, Lagrange S, Vermet H, Ojima I, Slayden RA.

PLoS One. 2014 Apr 15;9(4):e93953. doi: 10.1371/journal.pone.0093953. eCollection 2014.

9.

Design, synthesis and evaluation of novel 2,5,6-trisubstituted benzimidazoles targeting FtsZ as antitubercular agents.

Park B, Awasthi D, Chowdhury SR, Melief EH, Kumar K, Knudson SE, Slayden RA, Ojima I.

Bioorg Med Chem. 2014 May 1;22(9):2602-12. doi: 10.1016/j.bmc.2014.03.035. Epub 2014 Apr 1.

10.

Drug discovery targeting cell division proteins, microtubules and FtsZ.

Ojima I, Kumar K, Awasthi D, Vineberg JG.

Bioorg Med Chem. 2014 Sep 15;22(18):5060-77. doi: 10.1016/j.bmc.2014.02.036. Epub 2014 Mar 5. Review.

11.

SAR studies on trisubstituted benzimidazoles as inhibitors of Mtb FtsZ for the development of novel antitubercular agents.

Awasthi D, Kumar K, Knudson SE, Slayden RA, Ojima I.

J Med Chem. 2013 Dec 12;56(23):9756-70. doi: 10.1021/jm401468w. Epub 2013 Nov 23.

12.

Benzimidazole-based antibacterial agents against Francisella tularensis.

Kumar K, Awasthi D, Lee SY, Cummings JE, Knudson SE, Slayden RA, Ojima I.

Bioorg Med Chem. 2013 Jun 1;21(11):3318-26. doi: 10.1016/j.bmc.2013.02.059. Epub 2013 Apr 3.

13.

Therapeutic potential of FtsZ inhibition: a patent perspective.

Awasthi D, Kumar K, Ojima I.

Expert Opin Ther Pat. 2011 May;21(5):657-79. doi: 10.1517/13543776.2011.568483. Epub 2011 Mar 18. Review.

PMID:
21413908
14.

Discovery of anti-TB agents that target the cell-division protein FtsZ.

Kumar K, Awasthi D, Berger WT, Tonge PJ, Slayden RA, Ojima I.

Future Med Chem. 2010 Aug;2(8):1305-23. doi: 10.4155/fmc.10.220. Review.

15.

Novel trisubstituted benzimidazoles, targeting Mtb FtsZ, as a new class of antitubercular agents.

Kumar K, Awasthi D, Lee SY, Zanardi I, Ruzsicska B, Knudson S, Tonge PJ, Slayden RA, Ojima I.

J Med Chem. 2011 Jan 13;54(1):374-81. doi: 10.1021/jm1012006. Epub 2010 Dec 2.

Supplemental Content

Loading ...
Support Center